CHIMERIC ANTIGEN RECETOR T-CELL THERAPY - CAR T THERAPY

             Actually, CAR T-cell therapy represent options for ALL patients who have relapsed after intensive chemotherapy or a stem cell transplant. CAR T-cell therapy will be also an option for other blood cancer like  chronic lymphocytic leukemia (CLL), some types of non-Hodgkin lymphoma (NHL) including diffuse large B cell lymphoma (DLBCL), .... 

SITES

Chimeric Antigen Receptor (CAR) T-Cell Therapy  by LLS

TRIALS

Targeting Leukemic Stem Cell Expressing the IL-1RAP Protein in Chronic Myelogenous Leukemia (CML) (CAR-LMC)
July 22, 2016,  ClinicalTrials.gov

Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies     
June 27, 2016,  ClinicalTrials.gov              

VIDEOS

FDA announces first US gene therapy approval for cancer treatment
August 30, 2017, CNN
​

ARTICLES


Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
December 13, 2019, Dovepress

Dasatinib shows promise as a control agent for CAR T cells
July 5, 2019, MDedge

CML hematopoietic stem cells expressing IL-1RAP can be targeted by chimeric antigen receptor (CAR)-engineered T cells
December 4, 2018, American Association for Cancer Research

Maisonneuve Rosemont hospital getting $50 million for cancer treatment centre
July 7, 2016, CTV News Montreal  

93 percent of advanced leukemia patients in remission after immunotherapy
April 27, 2016, ScienceDaily

Excitement at new cancer treatment
February 16,2016, BBC.com    

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
2015, Journal Blood 

The CAR T-Cell Race
April 1, 2015, The Scientist

Chimeric antigen receptor T-cell therapy to target hematologic malignancies
November 15, 2014, PublMed                                       

 

                                    Return to Cure possible for CML?